| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $23.3M | -42.1% |
| SG&A Expense | $19.9M | -20.5% |
| Operating Income | -$49.3M | +30.0% |
| Income Tax | $0 | — |
| Net Income | -$45.5M | +29.7% |
| EPS (Basic) | -$14.35 | -1241.1% |
| EPS (Diluted) | -$14.35 | -1241.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $46.3M | +23.2% |
| Current Assets | $47.8M | -39.4% |
| Total Assets | $62.3M | -39.2% |
| Current Liabilities | $23.1M | +19.2% |
| Total Liabilities | $43.5M | +5.8% |
| Stockholders' Equity | $18.8M | -69.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$31.5M | +34.3% |
| Investing Cash Flow | $40.2M | -26.8% |
| Financing Cash Flow | $23K | -99.7% |